All Biosimilars Interchangeable? FDA Backs Switching With Spotlight On Science
Latest Review From US Agency Finds ‘Zero Difference’ In Risks When Switching
• By David Wallace
The FDA found biosimilar switching produced “zero difference” in key risks • Source: Shutterstock 
